Backed by decade of world class research

Our innovative platform

From the dark genome to novel treatments

Nucleome decodes genetic variation within the dark matter of the human genome to find new ways to treat diseases.

The dark genome makes up over 98% of our DNA which does not encode for proteins and is largely uncharted. It acts like an instruction manual that defines cell type specificity, switching genes on and off at the right time and level. This allows it to be able to translate the universal genome, present in human cells into multiple, differentiated cell types.

The dark genome contains the majority of the disease-linked genetic variants, most without a function currently ascribed. Nucleome has the tools to unlock its potential for drug target discovery and its associated biomarkers to develop therapeutics assets and treat diseases. This enables us to discover and develop better and safer drugs guided by genetics.

Our platform, based on decades of research from the University of Oxford, combines state of the art computational and experimental approaches invented to overcome the key challenges that hinder translation of the dark genome to novel treatments by defining.

The right variant

Nucleome’s machine learning model predicts disease-linked genetic variants that create and destroy functional elements in the dark genome

The right cell type

Nucleome’s machine learning model predicts the cell types affected by the genetic variants

The right gene

Nucleome’s 3D genome analysis methods link variants to genes experimentally

The right effect

Nucleome’s functional validation method defines the effect of genetic variants on the gene expression at scale in primary cell types

The right pathway

Nucleome’s assays are done at scale: allowing us to map disease affected pathways and understand how cell types are regulated in health and disease

Our 3D genome analysis methods offer significant benefits over other methods currently available:
Precision

on average 256 base pairs & our newest method published in Nature goes down to 1 base pair resolution

Confidence

Highest Sensitivity
Reproducible

Scalability

Highly Scalable
From single gene to every gene in the genome

Relevance

>100,000
cells required

Our research dramatically improves our understanding of how the dark genome drives diseases and has potential to discover novel high-quality targets guided by genetics across multiple diseases to build a robust pipeline of drug assets

Pipeline

The academic research that underpins Nucleome’s technology was originally focused on red blood cells and genetic variants associated with red blood cell traits. As a Company, Nucleome is focusing on lymphocytes and associated immune related diseases to transform disease outcomes in indications with great unmet need. Further details on our specific areas of focus will be available soon.

Partnerships

We are a leader in decoding the dark genome for drug discovery and development. Our unmatched expertise and know-how together with our innovative platform enables us to leverage disease-linked genetic variation in the dark genome to discover novel targets with corresponding biomarkers and to de-risk the existing ones.

We are passionate about bringing transformative discoveries to patients to deliver a new generation of precision medicines for complex diseases. Our interests lie in exploring new opportunities that are consistent with our mission. If you are interested in partnering with Nucleome, please contact us.